NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The expanded clinical cohort now includes 25 patients, with updated results showing that intranasal NEO100 has resulted in radiographic remission in 6 of 25 patients (24%). This response rate is higher than the 8% typically reported with salvage therapies for recurrent high-grade gliomas. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged dosing. The updated clinical results were presented in the company's announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-010101), on December 17, 2025, and is solely responsible for the information contained therein.